Advertisement

Pharmacologic Support of Critically ill Patients

  • K. P. Rothfield
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 28)

Abstract

Cardiovascular collapse is a devastating clinical entity frequently observed in both medical and surgical intensive care unit patients. Despite the gravity of this condition, advances in cardiovascular physiology, molecular biology, and pharmacology, now allow physicians to offer rational therapeutic interventions to such patients. This chapter will review the basic pathophysiology of cardiac failure, identify cellular targets for pharmacologic intervention, and discuss the actions and uses of some of the newer inotropic agents.

Keywords

Phosphodiesterase Inhibitor Inotropic Agent High Risk Surgical Patient Inotropic Therapy Surgical Intensive Care Unit Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Shore-Lesserson L, Konstadt S (1994) Recent advances in cardiac pharmacology. Anesth Clin North Am 12:133–168.Google Scholar
  2. 2.
    Lindeborg DM, Pearl RG (1993) Inotropic therapy in the critically ill patient. Int Anes Clin 31:49–71.CrossRefGoogle Scholar
  3. 3.
    Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB (1982) Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 307:205–211.PubMedCrossRefGoogle Scholar
  4. 4.
    Feldman MD, Copelas L, Gwathmey JK, Phillips SP, Warren SE, Schoen FJ, Grossman W, Morgan JP (1987) Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 75:331–339.PubMedCrossRefGoogle Scholar
  5. 5.
    Magrini F, Foulds R, Macchi G, Mondadori C, Zanchetti A (1987) Human renovascular effects of dopexamine hydrochloride: a novel agonist of peripheral dopamine and beta 2-adreno-re-ceptors. Eur J Clin Pharmacol 32:1–4.PubMedCrossRefGoogle Scholar
  6. 6.
    MacGregor DA, Butterworth JF 4th, Zaloga CP, Prielipp RC, James R, Royster RL (1994) Hemodynamic and renal effects of dopexamine and dobutamine in patients with reduced cardiac output following coronary artery bypass grafting. Chest 106:835–841.PubMedCrossRefGoogle Scholar
  7. 7.
    Boyd O, Lamb G, Mackey CJ, Grounds RM, Bennett ED (1995) A comparison of the efficacy of dopexamine and dobutamine for increasing oxygen delivery in high-risk surgical patients. Anasth & Int Care 23:478–484.Google Scholar
  8. 8.
    Smithies M, Yee TH, Jackson L, Beale R, Bihari D (1994) Protecting the gut and the liver in the critically ill: effects of dopexamine. Crit Care Med 22:789–795.PubMedCrossRefGoogle Scholar
  9. 9.
    Shoemaker W, Appel P, Kram H, Waxman K, Lee TS (1988) Prospective trial of supranormal values of survivors as therapeutic goas in high risk surgical patients. Chest 94:1176–1186.PubMedCrossRefGoogle Scholar
  10. 10.
    Boyd O, Grounds RM, Bennett ED (1994) A randomized clinical trial of the effect of deliberate perioperative increase of oxygen delivery on mortality in high-risk surgical patients. JAMA 270:2699–2707.CrossRefGoogle Scholar
  11. 11.
    Packer M, Carver J, Rodeheffer R, Ivanhoe R, Dibianco R, Zeldis S, Hendrix G, Bomner W, El-kayam U, Kukin M (1991) Effects of oral milrinone on mortality in severe congestive heart failure. N Engl J Med 325:1468–1475.PubMedCrossRefGoogle Scholar
  12. 12.
    Packer M (1993) The development of positive inotropic agents for chronic heart failure: how have we gone astray? J Am Coll Cardiol 22 (4 Suppl): 119A–126A.PubMedCrossRefGoogle Scholar
  13. Remme WJ(1993) Ino dilator therapy for heart failure. Early, late, or not at all? Circulation 87 (5 Suppl):IV97–107.Google Scholar
  14. 14.
    Shipley JB, Hess ML (1995) Inotropic therapy for the failing myocardium. Clin Cardiol 18:615–619.PubMedCrossRefGoogle Scholar
  15. 15.
    Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, White BG (1993) Effects of vesnarinone on morbidity and mortality in patients with heart failure, N Engl J Med 329:149–155.PubMedCrossRefGoogle Scholar
  16. 16.
    Hamilton MA (1993) Prevalence and clinical implications of abnormal thyroid hormone metabolism in advanced heart failure. Ann Thor Surg 56: S48–53.CrossRefGoogle Scholar
  17. 17.
    Holland FW II, Brown PS Jr, Weintraub BD, Clark RE (1991) Cardiopulmonary bypass and thyroid function: a "euthyroid sick syndrome." Ann Thorac Surg 52:46–50.PubMedCrossRefGoogle Scholar
  18. 18.
    Clark RE (1993) Cardiopulmonary bypass and thyroid hormone metabolism. Ann Thor Surg 56:S16–23.CrossRefGoogle Scholar
  19. 19.
    NovitzkyD, Cooper DKCChaffm JS, Greer AE, DeBault LE, Zuhdi N (1990) Improved cardiac allograft function following triiodothyronine therapy to both donor and recipient. Transplantation 49:311.PubMedCrossRefGoogle Scholar
  20. 20.
    Novitzky D, Cooper DKC, Barton CI, Greer A, Chaffin J, Grim J, Zuhid N (1989) Triiodothyronine as an inotropic agent after open heart surgery. J Thorc Cardiovasc Surg 98:972–978.Google Scholar
  21. 21.
    Davis PJ, Davis FB (1993) Acute cellular actions of thyroid hormone and myocardial function. Ann Thor Surg 56: S35–42.CrossRefGoogle Scholar
  22. 22.
    Dyke CM, Ding M, Abd-Elfattah AS, Loesser K, Dignan RJ, Wechsler AS, Slater DR (1993) Effects of triiodothyronine supplementation after myocardial ischemia. Ann Thorac Surg 56:215–222.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • K. P. Rothfield

There are no affiliations available

Personalised recommendations